|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
C4 Therapeutics, Inc. (CCCC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
69,340,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile C4 Therapeutics is a biopharmaceutical company engaged in the development of novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Co.'s primary product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. Co. is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E and RET programs for genetically defined resistant solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
1,159 |
1,159 |
1,159 |
| Total Sell Value |
$0 |
$3,651 |
$3,651 |
$3,651 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
2 |
2 |
2 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Grogan Donna Roy |
Director |
– • – |
2025-07-01 |
4 |
A |
$1.51 |
$14,510 |
D/D |
9,609 |
51,889 |
|
- |
|
| Anderson Kenneth Carl |
Director |
– • – |
2025-07-01 |
4 |
A |
$1.51 |
$11,500 |
D/D |
7,616 |
135,225 |
|
- |
|
| Grogan Donna Roy |
Director |
– • – |
2025-04-01 |
4 |
A |
$1.44 |
$13,749 |
D/D |
9,581 |
42,280 |
|
- |
|
| Anderson Kenneth Carl |
Director |
– • – |
2025-04-01 |
4 |
A |
$1.44 |
$11,252 |
D/D |
7,841 |
127,609 |
|
- |
|
| Boyle Scott N |
Chief Business Officer |
• – – |
2025-02-18 |
4 |
AS |
$3.15 |
$2,107 |
D/D |
(669) |
107,805 |
|
- |
|
| Hirsch Andrew |
President & CEO |
• • – |
2025-02-15 |
4 |
D |
$3.18 |
$29,797 |
D/D |
(9,370) |
423,145 |
|
- |
|
| Boyle Scott N |
Chief Business Officer |
• – – |
2025-02-14 |
4 |
D |
$3.18 |
$7,530 |
D/D |
(2,368) |
108,474 |
|
- |
|
| Boyle Scott N |
Chief Business Officer |
• – – |
2025-02-14 |
4 |
AS |
$3.15 |
$1,544 |
D/D |
(490) |
110,842 |
|
- |
|
| Boyle Scott N |
Chief Business Officer |
• – – |
2025-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
56,500 |
111,332 |
|
- |
|
| Hirsch Andrew |
President & CEO |
• • – |
2025-02-14 |
4 |
D |
$3.18 |
$40,853 |
D/D |
(12,847) |
432,515 |
|
- |
|
| Hirsch Andrew |
President & CEO |
• • – |
2025-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
223,500 |
445,362 |
|
- |
|
| Siegel Jolie |
Chief Legal Officer |
• – – |
2025-02-14 |
4 |
D |
$3.18 |
$9,267 |
D/D |
(2,914) |
107,939 |
|
- |
|
| Siegel Jolie |
Chief Legal Officer |
• – – |
2025-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
56,500 |
110,853 |
|
- |
|
| Mahaney Paige |
Chief Scientific Officer |
• – – |
2025-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
28,200 |
105,000 |
|
- |
|
| Schick Kelly |
Chief People Officer |
• – – |
2025-02-14 |
4 |
D |
$3.18 |
$7,530 |
D/D |
(2,368) |
108,885 |
|
- |
|
| Schick Kelly |
Chief People Officer |
• – – |
2025-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
56,500 |
111,253 |
|
- |
|
| Adams Kendra |
Chief Financial Officer |
• – – |
2025-02-14 |
4 |
D |
$3.18 |
$14,498 |
D/D |
(4,559) |
165,117 |
|
- |
|
| Adams Kendra |
Chief Financial Officer |
• – – |
2025-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
87,100 |
169,676 |
|
- |
|
| Mossler Mark |
Chief Accounting Officer |
• – – |
2025-02-14 |
4 |
D |
$3.18 |
$5,043 |
D/D |
(1,586) |
18,204 |
|
- |
|
| Reyno Leonard |
Chief Medical Officer |
• – – |
2025-02-14 |
4 |
D |
$3.18 |
$16,361 |
D/D |
(5,145) |
173,764 |
|
- |
|
| Reyno Leonard |
Chief Medical Officer |
• – – |
2025-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
87,100 |
178,909 |
|
- |
|
| Boyle Scott N |
Chief Business Officer |
• – – |
2025-02-13 |
4 |
D |
$3.20 |
$5,552 |
D/D |
(1,735) |
54,832 |
|
- |
|
| Siegel Jolie |
Chief Legal Officer |
• – – |
2025-02-13 |
4 |
D |
$3.20 |
$6,832 |
D/D |
(2,135) |
54,353 |
|
- |
|
| Schick Kelly |
Chief People Officer |
• – – |
2025-02-13 |
4 |
D |
$3.20 |
$5,552 |
D/D |
(1,735) |
54,753 |
|
- |
|
| Adams Kendra |
Chief Financial Officer |
• – – |
2025-02-13 |
4 |
D |
$3.20 |
$5,962 |
D/D |
(1,863) |
82,576 |
|
- |
|
222 Records found
|
|
Page 1 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
